original ) (raw )Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients
Qiuxiang Ou
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018
View PDFchevron_right
Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
Luís Cirnes
2021
View PDFchevron_right
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Roberta Minari
British Journal of Cancer
View PDFchevron_right
Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
Brigida Stanzione
International Journal of Molecular Sciences
View PDFchevron_right
Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report
Павел Тихвинский
Frontiers in Oncology, 2020
View PDFchevron_right
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
luis raez
Targeted Oncology
View PDFchevron_right
Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report
Brigida Stanzione
In Vivo, 2021
View PDFchevron_right
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
Ori Zelichov
Experimental Hematology & Oncology, 2019
View PDFchevron_right
Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy
Samantha Armstrong
Clinical Lung Cancer, 2019
View PDFchevron_right
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
Koichi Takayama
Cancers, 2019
View PDFchevron_right
Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib
José Luis Leal Fernández
Translational lung cancer research, 2021
View PDFchevron_right
Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer
Surein Arulananda
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017
View PDFchevron_right
Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
Matthew Milone
OncoTargets and Therapy, 2021
View PDFchevron_right
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Daniel Stetson
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017
View PDFchevron_right
Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients
Fortune Journals
View PDFchevron_right
Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
luis raez
Lung Cancer, 2017
View PDFchevron_right
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
Fabiana Bettoni
Lung Cancer, 2017
View PDFchevron_right
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Siow-ming Lee
The New England journal of medicine, 2017
View PDFchevron_right
Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report
Muneeb Rehman
JCO Precision Oncology, 2021
View PDFchevron_right
Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review
Zizheng Song
Annals of Palliative Medicine, 2021
View PDFchevron_right
Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
Takeshi Isobe
Cells
View PDFchevron_right
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Åslaug Helland
Lung Cancer
View PDFchevron_right
Latest Treatment Options to Overcome Acquired Resistance Toosimertinib for Egfr-Mutant Non-Small Cell Lung Cancer (NSCLC) After Prior Egfr-Tki Therapies
Lukman Tijani
2019
View PDFchevron_right
Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
Greta Catani
JTO Clinical and Research Reports
View PDFchevron_right
Clinical Response to Osimertinib Compared to Other Tyrosine Kinase Inhibitors and Chemotherapy in Non-Small Cell Lung Cancer
Carla Ríos , Fortune Journals
View PDFchevron_right
Osimertinib Resistance via Histologic Transformation From Non-small Cell Lung Carcinoma to Carcinosarcoma
paul stegelmeier
Curēus, 2024
View PDFchevron_right
Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M
harun iskandar
The Indonesian Biomedical Journal, 2023
View PDFchevron_right
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting
Wilfried Eberhardt
Journal of Cancer Research and Clinical Oncology, 2023
View PDFchevron_right
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
Hiroaki Akamatsu
Cancer science, 2018
View PDFchevron_right
T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer
Jacky Li
Oncotarget, 2018
View PDFchevron_right
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
Sofia Chico
Translational Lung Cancer Research
View PDFchevron_right
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
Edgardo Santos
Oncology and Therapy, 2018
View PDFchevron_right
Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR-mutated non-small cell lung cancer
Girolamo Crisi
Tumori Journal, 2018
View PDFchevron_right
Overcoming EGFR G724S -mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Matthias Scheffler
View PDFchevron_right